City
Epaper

Veeda Clinical Research Acquires European CRO - Heads - Expanding Global Reach & Capabilities

By ANI | Updated: March 26, 2024 16:55 IST

PRNewswireDublin [Ireland]/ Ahmedabad (Gujarat) [India], March 26: Veeda Clinical Research Limited, a full-service contract research organization (CRO) with ...

Open in App

PRNewswire

Dublin [Ireland]/ Ahmedabad (Gujarat) [India], March 26: Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology. Established in 2010, Heads has an operational presence in 25 multiple strategically important locations across Europe, North America and the Asia Pacific region. Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch.

Sharing details related to common synergies between Veeda and Heads, Dr. Mahesh Bhalgat, Group - CEO of Veeda Clinical Research, said, "With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the Oncology research. This equips Veeda to build long and enduring site relationships across geographies."

Elaborating on the prospects of this partnership, Binoy Gardi, Executive Vice Chairperson of Veeda Clinical Research, said, "As we integrate the operations of both the companies, this is an exciting opportunity for Veeda and Heads to expand markets, leverage complimentary capabilities and add value to our clients. We believe that our combined strengths will enable us to drive greater efficiency, innovation, and excellence in delivering research outcomes for drug development programs of our clients worldwide."

"There is a very strong cultural fit between Heads and Veeda," said Dr. George Kouvatseas, Partner, Heads. "Both companies share a dedication to scientific leadership, expansion of highly specialized services to meet the emerging needs of our clients, and an uncompromising focus on quality. During the integration phase, Heads will continue to offer uninterrupted support to client programs. The Veeda and Heads organization together are committed to nimble operations through a structured integration process without impact to ongoing client programs."

About Veeda Clinical Research Limited:

Veeda Clinical Research Limited ("Veeda") is one of the largest independent, full-service clinical research organizations, headquartered in Ahmedabad, India. Veeda offers a range of bioequivalence studies and early and late phase clinical trials. Veeda has successfully completed several regulatory inspections and is approved by USFDA, UK MHRA, ANVISA (Brazil), and WHO. Veeda has experience in conducting complex clinical studies. Visit https://www.veedacr.com/.

About Heads:

Heads is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with expertise in haemato-oncology studies. It provides complete range of clinical trial services, from start-up to completion, from Phase I to IV. In addition, it offers strategic oncology drug development consulting and expert advice, as the team understands the challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market. Visit https://heads-research.com/.

Media contact:

Siddharth Baad

Corporate Communications

Veeda Clinical Research

siddharth.b2274@veedacr.com

Logo: https://mma.prnewswire.com/media/2368181/Veeda_Heads_Logo.jpg

(ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire.will not be responsible in any way for the content of the same)

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

International'War is not India's choice': NSA Doval speaks to Chinese Foreign Minister Wang Yi amid India-Pak tensions

National'War is not India's choice': NSA Doval speaks to Chinese Foreign Minister Wang Yi amid India-Pak tensions

International"War not India's choice," says Doval while speaking with Chinese FM as he condemns the Pahalgam terror attack, urges for calm

NationalMP govt to organise regional agri-conclave in Narsinghpur, Satna

FootballHat-trick boy Danny Meitei relishes executing India's plan

Business Realted Stories

BusinessKudos to Govt's efforts under PM Modi leadership for ensuring peace, stability: NSE CEO

BusinessAdani Power to supply 1500 MW to Uttar Pradesh from upcoming greenfield power plant

BusinessIndiGo announces relief measures for affected passengers due to airport closure

BusinessAdani Power to supply 1,500 MW to UP from upcoming greenfield power plan

BusinessAdani Power to supply 1,500 MW to US from upcoming greenfield power plant